Literature DB >> 24240935

Trends in aortic valve replacement for elderly patients in the United States, 1999-2011.

José Augusto Barreto-Filho1, Yun Wang, John A Dodson, Mayur M Desai, Lissa Sugeng, Arnar Geirsson, Harlan M Krumholz.   

Abstract

IMPORTANCE: There is a need to describe contemporary outcomes of surgical aortic valve replacement (AVR) as the population ages and transcatheter options emerge.
OBJECTIVE: To assess procedure rates and outcomes of surgical AVR over time. DESIGN, SETTING, AND PARTICIPANTS: A serial cross-sectional cohort study of 82,755,924 Medicare fee-for-service beneficiaries undergoing AVR in the United States between 1999 and 2011. MAIN OUTCOMES AND MEASURES: Procedure rates for surgical AVR alone and with coronary artery bypass graft (CABG) surgery, 30-day and 1-year mortality, and 30-day readmission rates.
RESULTS: The AVR procedure rate increased by 19 (95% CI, 19-20) procedures per 100,000 person-years over the 12-year period (P<.001), with an age-, sex-, and race-adjusted rate increase of 1.6% (95% CI, 1.0%-1.8%) per year. Mortality decreased at 30 days (absolute decrease, 3.4%; 95% CI, 3.0%-3.8%; adjusted annual decrease, 4.1%; 95% CI, 3.7%- 4.4%) per year and at 1 year (absolute decrease, 2.6%; 95% CI, 2.1%-3.2%; adjusted annual decrease, 2.5%; 95% CI, 2.3%-2.8%). Thirty-day all-cause readmission also decreased by 1.1% (95% CI, 0.9%-1.3%) per year. Aortic valve replacement with CABG surgery decreased, women and black patients had lower procedure and higher mortality rates, and mechanical prosethetic implants decreased, but 23.9% of patients 85 years and older continued to receive a mechanical prosthesis in 2011. CONCLUSIONS AND RELEVANCE: Between 1999 and 2011, the rate of surgical AVR for elderly patients in the United States increased and outcomes improved substantially. Medicare data preclude the identification of the causes of the findings and the trends in procedure rates and outcomes cannot be causally linked. Nevertheless, the findings may be a useful benchmark for outcomes with surgical AVR for older patients eligible for surgery considering newer transcatheter treatments.

Entities:  

Mesh:

Year:  2013        PMID: 24240935      PMCID: PMC4089974          DOI: 10.1001/jama.2013.282437

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

1.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008.

Authors:  Jersey Chen; Sharon-Lise T Normand; Yun Wang; Harlan M Krumholz
Journal:  JAMA       Date:  2011-10-19       Impact factor: 56.272

2.  Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk.

Authors:  David S Bach; Derrick Siao; Steven E Girard; Claire Duvernoy; Benjamin D McCallister; Sarah K Gualano
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-10-27

3.  Aortic valve replacement in the elderly: determinants of late outcome.

Authors:  Elena A Ashikhmina; Hartzell V Schaff; Joseph A Dearani; Thoralf M Sundt; Rakesh M Suri; Soon J Park; Harold M Burkhart; Zhuo Li; Richard C Daly
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

4.  Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use--an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database.

Authors:  Joel Dunning; Haiyan Gao; John Chambers; Neil Moat; Gavin Murphy; Domenic Pagano; Simon Ray; James Roxburgh; Ben Bridgewater
Journal:  J Thorac Cardiovasc Surg       Date:  2011-10       Impact factor: 5.209

5.  Racial trends in the use of major procedures among the elderly.

Authors:  Ashish K Jha; Elliott S Fisher; Zhonghe Li; E John Orav; Arnold M Epstein
Journal:  N Engl J Med       Date:  2005-08-18       Impact factor: 91.245

6.  Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).

Authors:  R O Bonow; B Carabello; A C de Leon; L H Edmunds; B J Fedderly; M D Freed; W H Gaasch; C R McKay; R A Nishimura; P T O'Gara; R A O'Rourke; S H Rahimtoola; J L Ritchie; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R J Gibbons; R O Russell; T J Ryan; S C Smith
Journal:  Circulation       Date:  1998-11-03       Impact factor: 29.690

Review 7.  Aortic valve replacement in elderly patients: what are the limits?

Authors:  Lawrence H Cohn; Narendren Narayanasamy
Journal:  Curr Opin Cardiol       Date:  2007-03       Impact factor: 2.161

8.  An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction.

Authors:  Harlan M Krumholz; Yun Wang; Jennifer A Mattera; Yongfei Wang; Lein Fang Han; Melvin J Ingber; Sheila Roman; Sharon-Lise T Normand
Journal:  Circulation       Date:  2006-03-20       Impact factor: 29.690

9.  Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database.

Authors:  James M Brown; Sean M O'Brien; Changfu Wu; Jo Ann H Sikora; Bartley P Griffith; James S Gammie
Journal:  J Thorac Cardiovasc Surg       Date:  2009-01       Impact factor: 5.209

10.  Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses.

Authors:  P Bloomfield; D J Wheatley; R J Prescott; H C Miller
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

View more
  39 in total

1.  Validity of standard gamble utilities in patients referred for aortic valve replacement.

Authors:  Amjad I Hussain; Andrew M Garratt; Jan Otto Beitnes; Lars Gullestad; Kjell I Pettersen
Journal:  Qual Life Res       Date:  2015-11-24       Impact factor: 4.147

2.  The Effect of Dexmedetomidine on Outcomes of Cardiac Surgery in Elderly Patients.

Authors:  Hao Cheng; Zhongmin Li; Nilas Young; Douglas Boyd; Zane Atkins; Fuhai Ji; Hong Liu
Journal:  J Cardiothorac Vasc Anesth       Date:  2016-03-03       Impact factor: 2.628

3.  Valvular disease: Improving outcomes for aortic valve replacement in the USA.

Authors:  Tim Geach
Journal:  Nat Rev Cardiol       Date:  2013-12-10       Impact factor: 32.419

Review 4.  Cardioembolic Stroke.

Authors:  Hooman Kamel; Jeff S Healey
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

Review 5.  Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis.

Authors:  Haris Riaz; Shehab Ahmad Redha Alansari; Muhammad Shahzeb Khan; Talha Riaz; Sajjad Raza; Faraz Khan Luni; Abdur Rahman Khan; Irbaz Bin Riaz; Richard A Krasuski
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-05-10

Review 6.  Reoperative aortic valve replacement through upper hemisternotomy.

Authors:  Igor Gosev; Maroun Yammine; Marzia Leacche; Vladimir Ivkovic; Siobhan McGurk; Lawrence H Cohn
Journal:  Ann Cardiothorac Surg       Date:  2015-01

7.  Endothelial retention and phenotype on carbonized cardiovascular implant surfaces.

Authors:  Christopher M Frendl; Scott M Tucker; Nadeem A Khan; Mandy B Esch; Shrinidhi Kanduru; Thong M Cao; Andrés J García; Michael R King; Jonathan T Butcher
Journal:  Biomaterials       Date:  2014-06-20       Impact factor: 12.479

Review 8.  Geriatric Cardiology: An Emerging Discipline.

Authors:  John A Dodson; Daniel D Matlock; Daniel E Forman
Journal:  Can J Cardiol       Date:  2016-04-07       Impact factor: 5.223

9.  The gender paradox in TAVR.

Authors:  Anat Berkovitch; Israel M Barbash
Journal:  Ann Transl Med       Date:  2017-08

10.  A Comparison of Three Frailty Indices in Predicting Morbidity and Mortality After On-Pump Aortic Valve Replacement.

Authors:  Gary Esses; Evie Andreopoulos; Hung-Mo Lin; Shipra Arya; Stacie Deiner
Journal:  Anesth Analg       Date:  2018-01       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.